Efficacy of Dupilumab in Treating Atopic Dermatitis With Recurrent Eczema Herpeticum in a Patient With DOCK8-Deficiency Hyper-IgE Syndrome: A Case Report

The case study discusses the successful use of Dupilumab, a monoclonal antibody, in treating a six-year-old girl with DOCK8-deficiency hyper-IgE syndrome, a rare immunodeficiency disorder. The patient had chronic, disseminated eczema herpeticum and was administered 200 mg of Dupilumab every four weeks. By the time of her third dose, all active herpetic lesions had completely resolved, and no new lesions developed over the course of three months. Significant improvement was also observed in the patient's skin, scalp, hair restoration, and nails. The study concludes that while there is no cure-all for hyper-IgE syndrome, Dupilumab should be considered as a viable adjunctive treatment in similar cases.